Evidence map›Paper›PMID 31568710›Full record

ArticleMolecular genetics & genomic medicine2019

Osteosarcoma without prior retinoblastoma related to RB1 low-penetrance germline pathogenic variants: A novel type of RB1-related hereditary predisposition syndrome?

Marion Imbert-Bouteille, Marion Gauthier-Villars, Dominique Leroux, Isabelle Meunier, Isabelle Aerts, Livia Lumbroso-Le Rouic, Sophie Lejeune, Capucine Delnatte, Caroline Abadie, Pascal Pujol and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Frontiers in oncology · 2020
    Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Marion Imbert-BouteilleMedical Genetics Department, CHU Montpellier, Univ Montpellier, Montpellier, France.ORCID 0000-0002-8967-7004
Marion Gauthier-VillarsDepartment of Tumour Biology, Institut Curie, University Paris Descartes, Paris, France.
Dominique LerouxMedical Genetics Department, CHU Grenoble, Grenoble, France.
Isabelle MeunierNational Centre for Rare Diseases, Hereditary Retinal and Optic Nerve Disorders, CHU Montpellier, Univ Montpellier, Montpellier, France.
Isabelle AertsDepartment of Pediatric Oncology, Institut Curie, University Paris Descartes, Paris, France.
Livia Lumbroso-Le RouicDepartment of Ocular Oncology, Institut Curie, Paris, France.
Sophie LejeuneMedical Genetics Department, CHRU Lille, Lille, France.
Capucine DelnatteOncogenetics, Institut de Cancérologie de l'Ouest site René Gauducheau, Saint Herblain, France.
Caroline AbadieOncogenetics, Institut de Cancérologie de l'Ouest site René Gauducheau, Saint Herblain, France.
Pascal PujolMedical Genetics Department, CHU Montpellier, Univ Montpellier, Montpellier, France.
Claude HoudayerDepartment of Tumour Biology, Institut Curie, University Paris Descartes, Paris, France.
Carole CorsiniMedical Genetics Department, CHU Montpellier, Univ Montpellier, Montpellier, France.
Université de Montpellier · FRDélégation Paris 5 · FRInstitut de Cancérologie de l'Ouest · FRCentre Hospitalier Universitaire de Grenoble · FRCentre Hospitalier Universitaire de Lille · FRInstitut Curie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRetinoblastoma (Rb) is a rare intraocular malignant tumor in children with high overall survival. Predisposition to Rb is linked to RB1 germline mutations with high penetrance, but rare RB1 low-penetrance variants are also known. Rb survivors are at risk of second primary malignancies (SPMs), mostly osteosarcoma and soft-tissue sarcoma. Nevertheless, the risk of primary osteosarcoma developing without prior Rb has not been reported in RB1 germline mutation carriers.

methodsWe report a patient in whom osteosarcoma developed at age 17 as a first primary malignancy within a family context of sarcoma.

resultsUnexpectedly, genetic testing identified a low-penetrance germline mutation in RB1 [NM_000321.2: c.45_76dup; p.(Pro26Leufs*50)]. In eight additional similar cases from published and unpublished reports of families, first primary osteosarcomas and sarcomas mostly developed in RB1 low-penetrance mutation carriers without prior Rb.

conclusionWe propose that first primary sarcoma and osteosarcoma could be a novel clinical presentation of a RB1-related hereditary predisposition syndrome linked to RB1 low-penetrance germline mutations. In these families, careful screening of primary non-Rb cancer and SPMs is required by maintaining enhanced clinical vigilance. Implementing lifelong periodic whole-body MRI screening might be a complementary strategy for unaffected carrier relatives in these families.

Indexed as

Germ-Line MutationAdolescentBone NeoplasmsChemotherapy, AdjuvantFemaleGenetic Predisposition to DiseaseHumansInduction ChemotherapyMaleOrthopedic ProceduresOsteosarcomaPedigreePenetranceRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein Ligasescancer screeninglow penetranceOsteosarcomaRB1Sarcomawhole-body MRI

Identifiers

PMID31568710
PMCPMC6900371
OpenAlexW2979118358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.